Careers at Explicyte
Join a multidisciplinary team of cell biologists, immunologists, data scientists and medical oncologists working together at our immuno-oncology CRO in Bordeaux.
We recruit as our projects and capabilities grow. Explore our current opportunities or send us a spontaneous application.
What you'll find at Explicyte
25 scientific experts
Our multidisciplinary team brings together cell biologists, immunologists, medical oncologists and data scientists under one roof.
High-tech platforms
Spatial transcriptomics, single-cell technologies, proteomics and digital pathology. Each year, we invest approximately 15% of our revenue in R&D and scientific instrumentation, giving our teams access to advanced technologies for oncology research.
Science with impact
Based within Institut Bergonié Comprehensive Cancer Center, we work closely with clinicians and drug developers to advance novel immunotherapy strategies.
Roles we're hiring for
No open positions right now
We hire as projects grow. If your expertise fits our work in immuno-oncology, send a spontaneous application — we read every one.
Send a spontaneous applicationDon’t see a role that fits? We still want to hear from you.
Send a spontaneous applicationOur story
-
2012–2014
ImmuSmol's in vivo services
In 2012, after completing his postdoctoral research, immunologist Alban Bessède founded ImmuSmol, a biotech company developing antibodies against kynurenine-pathway metabolites for diagnostic and therapeutic applications. Drawing on his expertise in syngeneic tumor models and immune checkpoint inhibitors, Immusmol also began providing preclinical research services to support its internal R&D activities.
-
2015–2019
Launch of Explicyte Immuno-Oncology
In 2015, ImmuSmol launched a dedicated brand for its contract-research activity in immuno-oncology: Explicyte. The company expanded its capabilities across in vitro screening, immune profiling and preclinical oncology research. At the time, the company was located at the Biomedical Innovation Platform of the University of Bordeaux.
-
2020–2024
Pivot toward translational research
In 2020, the company moved to the Bergonié Comprehensive Cancer Center. Close collaboration with medical oncologists led the company to develop translational research projects and build a precision medicine platform. Scientific collaborations resulted in high-impact publications and team reinforcement with PhDs and MDs.
-
2025 onward
Multiomics & clinical focus
To reinforce its multiomics capabilities, Explicyte acquired the full range of 10x Genomics platforms in 2025 and became a certified 10x Genomics service provider. As a first step toward supporting clinical trials, the company earned ISO 9001 and ISO 13485 certification for its digital pathology and histology operations — the foundation for developing and analyzing oncology biomarkers.
In their own words
Life at Explicyte
Close to the city center
We're at the Institut Bergonié, a ten-minute walk from central Bordeaux. Come by train, tram, or bike — we cover 50% of your public-transport pass.
A house with a garden
In 2024 we moved into a freshly renovated house next to the Institut Bergonié — a place for focused work, meetings, lunch, and social events.
Support for parents
We provide access to childcare places and offer flexible working hours to help parents balance work and family life.
